BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21640495)

  • 1. Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy.
    Meyer F; Fortin A; Wang CS; Liu G; Bairati I
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1454-62. PubMed ID: 21640495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients.
    Bairati I; Meyer F; Gélinas M; Fortin A; Nabid A; Brochet F; Mercier JP; Têtu B; Harel F; Abdous B; Vigneault E; Vass S; Del Vecchio P; Roy J
    J Clin Oncol; 2005 Aug; 23(24):5805-13. PubMed ID: 16027437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients.
    Bairati I; Meyer F; Gélinas M; Fortin A; Nabid A; Brochet F; Mercier JP; Têtu B; Harel F; Mâsse B; Vigneault E; Vass S; del Vecchio P; Roy J
    J Natl Cancer Inst; 2005 Apr; 97(7):481-8. PubMed ID: 15812073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute adverse effects of radiation therapy and local recurrence in relation to dietary and plasma beta carotene and alpha tocopherol in head and neck cancer patients.
    Meyer F; Bairati I; Jobin E; Gélinas M; Fortin A; Nabid A; Têtu B
    Nutr Cancer; 2007; 59(1):29-35. PubMed ID: 17927499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly.
    Allal AS; Maire D; Becker M; Dulguerov P
    Cancer; 2000 Feb; 88(3):648-52. PubMed ID: 10649260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system.
    Palazzi M; Tomatis S; Orlandi E; Guzzo M; Sangalli C; Potepan P; Fantini S; Bergamini C; Gavazzi C; Licitra L; Scaramellini G; Cantu' G; Olmi P
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):330-7. PubMed ID: 17881148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment.
    Al-mamgani A; Tans L; Van rooij PH; Noever I; Baatenburg de jong RJ; Levendag PC
    Acta Oncol; 2009; 48(4):562-70. PubMed ID: 19373698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute toxicities experienced during simultaneous integrated boost intensity-modulated radiotherapy in head and neck cancers--experience from a north Indian regional cancer centre.
    Chakraborty S; Ghoshal S; Patil V; Oinam A; Suresh S
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):676-86. PubMed ID: 19748768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer.
    Zouhair A; Azria D; Pasche P; Stupp R; Chevalier J; Betz M; Mirimanoff RO; Ozsahin M
    Radiother Oncol; 2004 Feb; 70(2):183-8. PubMed ID: 15028406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer.
    Rades D; Stoehr M; Meyners T; Bohlen G; Nadrowitz R; Dunst J; Schild SE; Wroblewski J; Albers D; Schmidt R; Alberti W; Tribius S
    Strahlenther Onkol; 2008 Apr; 184(4):198-205. PubMed ID: 18398584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3).
    Bjarnason GA; Mackenzie RG; Nabid A; Hodson ID; El-Sayed S; Grimard L; Brundage M; Wright J; Hay J; Ganguly P; Leong C; Wilson J; Jordan RC; Walker M; Tu D; Parulekar W;
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):166-72. PubMed ID: 18805649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective study of palliative radiotherapy in newly diagnosed head and neck carcinoma.
    Stevens CM; Huang SH; Fung S; Bayley AJ; Cho JB; Cummings BJ; Dawson LA; Hope AJ; Kim JJ; O'Sullivan B; Waldron JN; Ringash J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):958-63. PubMed ID: 20950952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer.
    Nourissat A; Bairati I; Samson E; Fortin A; Gélinas M; Nabid A; Brochet F; Têtu B; Meyer F
    Cancer; 2010 May; 116(9):2275-83. PubMed ID: 20187097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
    Yen SH; Wang LW; Lin YH; Jen YM; Chung YL
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1463-70. PubMed ID: 21840136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
    Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
    Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.